Single high dose-large field irradiation in drug resistant non-Hodgkin's lymphoma.
Single high dose-large field irradiation (SHD-LFI), also described as half-body irradiation (HBI), has previously been reported as an effective modality for the palliation of symptoms in a number of solid tumors. This report concerns the ability of SHD-LFI to produce palliation of symptoms and/or objective response in patients with drug resistant non-Hodgkin's lymphoma (NHL). From 1981 to 1984, 34 patients with advanced drug resistant NHL were treated with SHD-LFI either to the whole abdomen (24 patients) or to the upper half body (10 patients). Overall, 19 of 23 patients achieved symptomatic improvement, while objective response was noted in 23 of 30 patients. We noted subjective and objective response in all histologies, and duration of response was not significantly different. Our results suggest a beneficial role for the early and judicious use of SHD-LFI in NHL.
D004307:Dose-Response Relationship, Radiation; D004351:Drug Resistance; D005069:Evaluation Studies as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D010166:Palliative Care